It’s now autumn, and I always feel sorrowful and morose during this season. Plus now, with the coronavirus I feels even more depressed. What can I do in order to cheer me up?

Thank you so much for your question, you’re certainly not alone in feeling this way right now. When the weather changes in fall and winter, it’s not uncommon for people to experience tough feelings for a number of reasons – it’s getting darker earlier, we may be spending more time indoors than we might normally like to, and it can […]

Continue reading »

surufatinib

surufatinib Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors Hong Kong, Shanghai, & Florham Park, NJ: Monday, December 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has initiated the filing of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) – the […]

Continue reading »

VP-102

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum WEST CHESTER, PA – Dec. 23, 2020 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment […]

Continue reading »

Toxin provides clues to long-term effects of diarrhea caused by E. coli

For people in wealthy countries, diarrhea is usually nothing more than an uncomfortable inconvenience for a few days. But for a poor child in a developing country, repeated bouts of diarrhea can lead to serious health consequences such as malnutrition, stunted growth and cognitive deficits. Researchers at Washington University School of Medicine in St. Louis have discovered that a toxin […]

Continue reading »

sutimlimab

sutimlimab FDA Issues Complete Response Letter for Sutimlimab, an Investigational Treatment for Hemolysis in Adults with Cold Agglutinin Disease PARIS – November 13, 2020 – The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sutimlimab, an investigational monoclonal antibody for the treatment of hemolysis in adults with cold agglutinin disease. The […]

Continue reading »

HTX-011

Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain SAN DIEGO, Nov. 13, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the New Drug Application (NDA) was resubmitted to […]

Continue reading »

ALKS 3831

FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder DUBLIN, Oct. 9, 2020 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA). The committees met to discuss ALKS 3831 (olanzapine/samidorphan), an investigational, novel, […]

Continue reading »
1 144 145 146 147 148 160